Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 30.06.2021.

#medicalnews
#IP
#viruses
#microbiome
#NBThighlight
#TCR
#biopharma
#COVID19
#GoodDayBIO
#COVID19Vaccines

Companies And Industries

@biospace shared
On Jun 28, 2021
Clinical Catch-Up: June 21-25 #biopharma #medicalnews https://t.co/UALLajjbWt
Open
Clinical Catch-Up: June 21-25

Clinical Catch-Up: June 21-25

It was a busy week for clinical trial news. Here’s a look.

@jgi shared
On Jun 28, 2021
Read "Metagenomic compendium of 189,680 DNA #viruses from the human gut #microbiome" in @NatureMicrobiol from team incl. Stephen Nayfach @kyrpides @DaviPaez @LBNLBioSci @BerkeleyLab, @PhilHugenholtz @HSberro @mfgrp: https://t.co/dTbzt0d0UL
Open
Metagenomic compendium of 189,680 DNA viruses from the human gut microbiome

Metagenomic compendium of 189,680 DNA viruses from the human gut microbiome

Almost 190,000 draft-quality DNA virus genomes are recovered by mining more than 11,000 deposited human stool metagenomes to improve resources for understanding the human gut virome.

@KBIBiopharma shared
On Jun 29, 2021
Along with Selexis SA, we signed a service agreement with Immatics to advance the GMP process development activities for their #TCR Bispecifics IMA402 program towards the Investigational New Drug (IND) stage and clinical development. https://t.co/1kCjZLlORH https://t.co/rciSMV2iAB
Open
Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND

Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND

Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND

@biospace shared
On Jun 25, 2021
Four pharma companies debut on @Nasdaq this morning #stockmarket #medicalnews https://t.co/De3imc6tYt
Open
Four Pharma Companies Debut on Nasdaq This Morning

Four Pharma Companies Debut on Nasdaq This Morning

Multiple biopharma companies make their first appearance on the Nasdaq this morning to advance the next-generation therapeutics. BioSpace takes a look at some of these IPOs.

@IAmBiotech shared
On Jun 25, 2021
Nearly 300 global biotechnology companies and associations have come together in opposition to waiving #IP protections for #COVID19 vaccines and treatments—explaining why the move would harm not only this pandemic response, but also the next one. https://t.co/CjKKaYSuUx
Open
A Declaration from Members of the World’s Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property

A Declaration from Members of the World’s Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property

The undersigned CEOs of global biotechnology companies and associations have a social responsibility to work with other stakeholders – healthcare providers, governments, multilateral ...

@IAmBiotech shared
On Jun 24, 2021
#GoodDayBIO: Nearly 300 global biotechnology companies and associations have come together in opposition to waving #IP protections for #COVID19Vaccines. Plus, a look at why #climate solutions must be rooted in biotechnology. https://t.co/JWBFNbxlb6
Open
Good Day BIO: The world’s biotech sector unites to oppose IP waiver | BIO

Good Day BIO: The world’s biotech sector unites to oppose IP waiver | BIO

Today, biotech companies of all sizes from around the world have united on an issue that could have a huge impact on the pandemic, patients, and future cures—we have the details. We also ...

@FierceBiotech shared
On Jun 29, 2021
Investor expectations were high for NTLA-2001, and analyst after analyst said the results blew away their predictions https://t.co/i6sHfuTKXS
Open
Intellia hits a 'home run' with gene editing results, setting up entire field for a grand slam

Intellia hits a 'home run' with gene editing results, setting up entire field for a grand slam

Intellia’s gene editing results “decisively exceeded” analyst expectations, launching the rest of the field into the spotlight overnight and maybe, just maybe, providing some fodder for the ...

@FierceBiotech shared
On Jun 29, 2021
The failure sent shares in Cel-Sci down 45% https://t.co/KcWQLlbH0H
Open
Cel-Sci's 11-year cancer drug odyssey ends in failure, sinking stock, but plots FDA filing anyway

Cel-Sci's 11-year cancer drug odyssey ends in failure, sinking stock, but plots FDA filing anyway

A phase 3 clinical trial of Cel-Sci’s immunotherapy candidate has missed its primary endpoint. The drug failed to improve on the overall survival achieved by standard of care in the overall ...